Pharmaceuticals, Biotechnology & Life Sciences

United Therapeutics insider trades: Martine Rothblatt’s 10(b)(5) buys and sells show confidence in the firm’s pipeline and strategic liquidity management while keeping ownership stable.

AbbVie’s newest biologic launches—Product A for ulcerative colitis and Product B for triple‑negative breast cancer—boost its pipeline and signal strong upside amid a booming antibody‑therapeutics market.

Explore Sartorius AG’s 2026 mid‑year performance: steady profits, AI‑driven growth, and debt‑free resilience in a volatile market—ideal for tech‑focused investors.

Pfizer teams with Japan’s Eisai to launch migraine drug Nurtec, boosting market reach and navigating regulatory hurdles—while a NYC office‑to‑residence project faces a stop‑work order over cracked beams, highlighting shared risk management across se…

Novo Nordisk shares rise 3% in Copenhagen amid cautious optimism, as investors weigh GLP‑1 success, new amylin therapy, and competitive pressures in the obesity‑drug market.

Johnson & Johnson’s $5.5 B talc settlement: how the payout, investor confidence, and product‑liability risks reshape its finances and brand.

Danaher’s Q2 shows 12% life‑sciences and 10% diagnostics revenue growth, fueling a 6% EPS rise and bolstering investor confidence with a strong R&D pipeline.

Alnylam strengthens its RNA‑medicine pipeline by adding Dr. Laura Sepp‑Lorenzino to the Scientific Advisory Board, boosting CRISPR‑RNAi expertise and clinical‑trial strategy.

Merck’s Phase III success with sonesitatug vedotin shows first‑in‑class CLDN18.2‑targeted therapy for gastric cancer, offering new survival benefits and a clear value‑based pricing strategy.

Incyte’s latest executive option exercises reveal a strategic focus on TSR‑linked incentives and retention, hinting at confidence in growth while spotlighting dilution risks and competitive dynamics.